Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury
NCT05951777Phase 2Recruiting
- Sponsor
- Hope Biosciences
- Start
- Apr 2024
- Primary completion
- Dec 2027
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of allogeneic HB-adMSCs in traumatic brain injury (TBI) (2 arms), sponsored by Hope Biosciences. Primary endpoints: Glucose at 1 year, Calcium at 1 year and 36 more. Started Apr 2024; status: recruiting.
02
Drugs
allogeneic HB-adMSCs
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on NCT05951777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05951777.